SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

  • Post author:
  • Post category:uncategorized

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular…

Continue ReadingSELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes